Inclusion criteria:

          -  Participant must have histologically or cytologically confirmed solid malignancy that
             is metastatic or unresectable and which may derive benefit from epidermal growth
             factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase
             receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor
             types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head
             and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell
             cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC),
             mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have
             either progressed after prior standard of care therapy for metastatic disease, be
             ineligible for, or have refused all other currently available therapeutic options. In
             cases where participants refuse currently available therapeutic options, this must be
             documented in the study records

          -  Participant must have ECOG performance status of 0 or 1

          -  A woman of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test
             within 24 hours before the first dose of study drug

          -  A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for 6 months after receiving the last dose of study
             drug

          -  A man who is sexually active with a woman of childbearing potential must agree to use
             a condom and his partner must also be practicing a highly effective method of
             contraception (that is, established use of oral, injected or implanted hormonal
             methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine
             system [IUS])

        Exclusion criteria:

          -  Participant has uncontrolled inter-current illness, including but not limited to
             poorly controlled hypertension or diabetes, ongoing or active systemic infection (that
             is, has discontinued all antibiotics for at least one week prior to first dose of
             study drug), or psychiatric illness/social situation that would limit compliance with
             study requirements, including ability to self-care for anticipated toxicities (that
             is. rash or paronychia). Participants with medical conditions requiring chronic
             continuous oxygen therapy are excluded

          -  Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an
             investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer,
             before the first administration of study drug; or participant has received prior
             immunotherapy within 6 weeks before the first administration of study drug. For agents
             with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities
             from previous anticancer therapies should have resolved to baseline levels or to Grade
             1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2
             peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone
             replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved
             to baseline levels

          -  Participants with untreated brain metastases. Participants with locally treated
             metastases that are clinically stable and asymptomatic for at least 2 weeks and who
             are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg]
             prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible

          -  Participant has an active malignancy other than the disease under study requiring
             treatment

          -  Participant has leptomeningeal disease